2026-09-03T09:32:41-05:00 2025-12-31 131655065 LUTZ AND CARR CPAS LLP 551 FIFTH AVENUE SUITE 400 NEW YORK NY 10176 990 2025-01-01 582492929 LUPUS RESEARCH ALLIANCE INC LUPU 6468846000 52 VANDERBILT AVE SUITE 401 NEW YORK NY 10017 DEBRA ROSE CHIEF FINANCIAL OFFICER 6468846000 2026-09-02 1 JENNIFER COATES P02247728 2126972299 2025 DEBRA ROSE 52 VANDERBILT AVE SUITE 401 NEW YORK NY 10017 42977371 0 X LUPUSRESEARCH.ORG X 1999 NY FREEING THE WORLD OF LUPUS. 23 23 71 500 0 0 11172604 12046822 1874491 2057382 4937822 9021341 570065 575904 18554982 23701449 15491102 16051336 0 0 11287230 13162673 75000 78000 4884285 11322100 12857921 38175432 42149930 -19620450 -18448481 93254416 88318156 37541841 39640029 55712575 48678127 X PUTTING PEOPLE WITH LUPUS AT THE CENTER OF ALL WE DO, THE LUPUS RESEARCH ALLIANCE DRIVES THE DISCOVERY & DEVELOPMENT OF NEXT GENERATION LUPUS DIAGNOSTICS AND CURATIVE TREATMENTS THROUGH INNOVATIVE RESEARCH & COLLABORATIONS. 0 0 15426770 12958702 THE LUPUS RESEARCH ALLIANCE (LRA), THE LARGEST NON-GOVERNMENTAL, PRIVATE FUNDER OF LUPUS RESEARCH WORLDWIDE. THE ORGANIZATION'S RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD INCLUDES TOP SCIENTIFIC EXPERTS, AND KEY LAY MEMBERS OF THE LRA'S BOARD OF DIRECTORS, WHO WORK WITH STAFF TO STRATEGICALLY GUIDE AND DRIVE THE RESEARCH FUNDING AGENDA. THE LRA FUNDS INNOVATIVE RESEARCH THAT SPANS THE SPECTRUM FROM FOUNDATIONAL TO CLINICAL RESEARCH. THE LRA HAS INVESTED NEARLY $228 MILLION IN LUPUS RESEARCH GRANTS INCLUDING 675+ RESEARCH GRANTS. IN 2025 OVER $12 MILLION WAS AWARDED IN GRANTS FOR OVER 31 HIGHLY INNOVATIVE PROJECTS WITH THE POTENTIAL TO IMPROVE TREATMENT AS WELL AS UNDERSTAND THE CAUSES OF LUPUS AND THUS LEAD TO A CURE. BELOW IS A SUMMARY OF RESEARCH GRANTS AND PROGRAMS FUNDED BY THE LRA IN 2025: 6 LUPUS INNOVATION AWARD GRANTS WERE AWARDED TOTALING OVER $2 MILLION OVER TWO YEARS, THIS PROGRAM SUPPORTS PIONEERING, HIGH-RISK, HIGH-REWARD PROJECTS ADDRESSING MAJOR CHALLENGES IN LUPUS RESEARCH. EARLY-STAGE INVESTIGATORS ARE GIVEN SPECIAL CONSIDERATION DURING THE REVIEW PROCESS AND ARE ELIGIBLE FOR A THIRD YEAR OF FUNDING; 7 EMPOWERING LUPUS RESEARCH ADMINISTRATIVE SUPPLEMENT GRANTS WERE AWARDED TOTALING $180,000. THIS PROGRAM SUPPORTS PROMISING TRAINEES WHO ARE WORKING WITH LRA-FUNDED RESEARCHERS OR INVESTIGATORS FOCUSED ON AUTOIMMUNITY SUPPORTED BY THE NATIONAL INSTITUTES OF HEALTH, DEPARTMENT OF DEFENSE, OR EQUIVALENT GRANTS IN GOOD STANDING.2 MECHANISTIC CLINICAL AWARDS WERE AWARDED TOTALING ALMOST $1.5 MILLION TO DEEPEN OUR EXPLORATION OF LIFESTYLE INTERVENTIONS IN A NIMBLER CLINICAL TESTING FRAMEWORK. THE AWARD PROVIDES FUNDS FOR PILOT STUDIES TESTING LIFESTYLE INTERVENTIONS IN CONCERT WITH HYPOTHESIS-DRIVEN MECHANISTIC ANALYSIS TO ILLUMINATE THE UNDERLYING EFFECTS OF LUPUS.2 GLOBAL TEAM SCIENCE AWARDS (GTSA) TOTALING ALMOST $6 MILLION TO SUPPORT INTERDISCIPLINARY, COLLABORATIVE, AND HIGHLY SYNERGISTIC PROJECTS THAT FOCUS ON THE MOLECULAR UNDERSTANDING OF HUMAN LUPUS AND THE HETEROGENEITY OF THE DISEASE. THESE AWARDS ALSO INCLUDE PLANNING GRANTS THAT SUPPORT RESEARCHERS IN PREPARING COMPETITIVE FULL APPLICATIONS.1 CROSS COLLABORATIVE GTSA SUPPLEMENT FOR 230K TO ENCOURAGE FURTHER SYNERGIES AND FOSTER THE CROSS-POLLINATION OF IDEAS ACROSS FUNDED GTSA TEAMS. BY MAXIMIZING THE POTENTIAL WITHIN THE GTSA PROGRAM, THE LRA AIMS TO PUSH THE BOUNDARIES OF PATIENT-CENTRIC RESEARCH, GENERATING COLLECTIVE KNOWLEDGE ON DISEASE HETEROGENEITY AND LEADING TO INNOVATIVE APPROACHES TO THERAPEUTIC TREATMENTS AND DISCOVERIES THAT WILL SHAPE THE FUTURE OF LUPUS RESEARCH AND CLINICAL TRANSLATION. 4 EMPOWERING LUPUS RESEARCH CAREER DEVELOPMENT AWARDS TOTALING $1.8 MILLION SUPPORTING OUTSTANDING EARLY-CAREER SCIENTISTS WHO REFLECT THE COMMUNITIES AND POPULATIONS OF PEOPLE LIVING WITH LUPUS. THIS AWARD PROVIDES FUNDS FOR AWARDEES TO ESTABLISH A COMPETITIVE INDEPENDENT RESEARCH PROGRAM IN THE LUPUS RESEARCH COMMUNITY.1 EMPOWERING LUPUS RESEARCH POSTDOCTORAL AWARD FOR $200K TO SUPPORT PROMISING SCIENTIST WHO REFLECTS THE COMMUNITIES AND POPULATIONS OF PEOPLE LIVING WITH LUPUS. THE AWARD PROVIDES SUPPORT FOR AWARDEES TO GENERATE THE SCIENTIFIC DATA AND UNIQUE RESEARCH IDEAS NECESSARY TO ULTIMATELY TRANSITION TO AN INDEPENDENT LUPUS RESEARCHER ROLE.IN ADDITION TO ITS TRADITIONAL GRANTS, THE LRA AWARDED THE LUPUS INSIGHT PRIZE, A $100,000 AWARD THAT RECOGNIZES A LEADING RESEARCHER WHO HAS MADE A MAJOR CONTRIBUTION RELEVANT TO LUPUS. THE PRIZE RECOGNIZES AND HONORS SIGNIFICANT SCIENTIFIC INSIGHTS THAT ADVANCE UNDERSTANDING OF THE CAUSES, PATHOGENESIS, OR TREATMENT OF LUPUS.AS PART OF ITS COMMITMENT TO COLLABORATION, THE LRA CONTINUED IN 2025 TO WORK WITH PARTNERS ACROSS SECTORS TO ACCELERATE RESEARCH DISCOVERIES, LEVERAGE RESOURCES, AND EXPEDITE THE DRUG DEVELOPMENT PROCESS. BY BRINGING TOGETHER KEY CONTRIBUTORS IN THE FIGHT AGAINST LUPUS--INCLUDING GRANTEES, SCIENTIFIC ADVISORS, CLINICIANS, THE BIOPHARMACEUTICAL INDUSTRY, THE U.S. GOVERNMENT, AND PEOPLE LIVING WITH LUPUS--THE LRA AIMS TO IMPROVE QUALITY OF LIFE FOR THOSE AFFECTED BY THE DISEASE.THE LRA'S ROBUST FUNDING MODEL SUPPORTS PROMISING RESEARCH EFFORTS DESIGNED TO IMPROVE THE LIVES OF PEOPLE WITH LUPUS. THROUGH A COMPETITIVE PEER-REVIEW PROCESS, THE LRA SUPPORTS PROJECTS THAT AIM TO TRANSLATE RESEARCH FINDINGS FROM THE BENCH TO THE BEDSIDE AS QUICKLY AS POSSIBLE. 17084288 3052329 2057382 THE LUPUS RESEARCH ALLIANCE (LRA) ADVANCED ITS SCIENTIFIC MISSION IN 2025 BY STRENGTHENING ITS RESEARCH STRATEGY, EXPANDING OPERATIONAL GRANTMAKING ACTIVITIES, AND ADVANCING COLLABORATIVE INITIATIVES DESIGNED TO ACCELERATE PROGRESS IN LUPUS DIAGNOSIS, TREATMENT, AND CLINICAL TRIAL READINESS.IN 2025, LRA IMPLEMENTED THE SECOND YEAR OF ITS 2024-2028 RESEARCH STRATEGY. AS PART OF THIS WORK, LRA RENEWED THE COMMON MECHANISMS IN AUTOIMMUNE DISEASES PROGRAM AND ADVANCED PLANNING FOR BIOMARKER AND DATA STRATEGIES INTENDED TO SUPPORT MORE PRECISE, EFFICIENT, AND COLLABORATIVE LUPUS RESEARCH.LRA'S GRANTMAKING PROGRAMS, INCLUDING THE GLOBAL TEAM SCIENCE AWARD, EMPOWERING RESEARCH PROGRAM, LUPUS INNOVATION AWARD, TRANSLATIONAL BRIDGE AWARD, AND MECHANISTIC CLINICAL TRIAL AWARD, CONTINUED TO SUPPORT INNOVATIVE AND TRANSLATIONAL LUPUS RESEARCH. DURING 2025, LRA ALSO RELEASED MULTIPLE REQUESTS FOR APPLICATIONS THROUGH THE GLOBAL TEAM SCIENCE AWARD AND CONTINUED THE ADMINISTRATIVE SUPPLEMENT TRAINING PROGRAM TO HELP STRENGTHEN THE LUPUS RESEARCH WORKFORCE. TO INCREASE AWARENESS OF ITS SCIENTIFIC PROGRAMS AND RESEARCH FINDINGS, LRA PRESENTED WORK AT MAJOR SCIENTIFIC MEETINGS AND CONVENED ITS ANNUAL FORUM FOR DISCOVERY AND ADDITIONAL PROGRAM-SPECIFIC INVESTIGATOR MEETINGS.OPERATIONAL IMPROVEMENTS INCLUDED THE SELECTION AND IMPLEMENTATION OF A NEW GRANT MANAGEMENT SYSTEM, THE RECRUITMENT AND ONBOARDING OF STAFF MEMBERS INCLUDING ADMINISTRATORS AND SCIENTISTS AND CONTINUING THE STRENGTHENING OF THE RESEARCH TEAM THROUGH TARGETED TEAM-BUILDING AND PROFESSIONAL DEVELOPMENT EFFORTS. LUPUS ABC HAS BEEN SUCCESSFULLY ESTABLISHED AS A MODEL PUBLIC-PRIVATE PARTNERSHIP IN THE REGULATORY SPACE, DEMONSTRATING LEADERSHIP AND INNOVATION IN ADVANCING LUPUS THERAPY DEVELOPMENT. SINCE ITS LAUNCH, PARTICIPATION IN LUPUS ABC, INCLUDING ENGAGEMENT FROM THE FDA, HAS GROWN THREEFOLD, HIGHLIGHTING THE CONSORTIUM'S CONVENING POWER AND COLLABORATIVE INFLUENCE. WORKS FROM LUPUS ABC HAS RESULTED IN FIVE PUBLICATIONS, INCLUDING ONE WITH THE FDA'S ACKNOWLEDGMENT OF CLASI 70 AS A PRIMARY EFFICACY ENDPOINT IN CUTANEOUS LUPUS CLINICAL TRIALS, MARKING A SIGNIFICANT ADVANCEMENT IN CLINICAL OUTCOME MEASUREMENT. IN ADDITION, LUPUS ABC LAUNCHED THREE NEW WORKING GROUPS, TWO OF WHICH FOCUS ON PATIENT-REPORTED OUTCOMES (PRO) TO FURTHER INTEGRATE PATIENT PERSPECTIVES INTO RESEARCH AND REGULATORY STRATEGIES. THE THIRD WORKING GROUP CENTERS ON IMMUNE RESET THERAPIES, A RAPIDLY EVOLVING FIELD WITH PROMISING POTENTIAL FOR INDIVIDUALS WITH LUPUS. IN 2025, LUPUS ABC RELEASED ITS FIRST REQUEST FOR PROPOSALS (RFP) WITH NEW PROJECTS SELECTED FOR SUPPORT TO BE ANNOUNCED IN MID-2026.LUPUS NEXUS COMPLETED ITS INFRASTRUCTURE BUILD AND OFFICIALLY LAUNCHED TO BOTH RESEARCH AND PATIENT COMMUNITIES. IT FINALIZED FOUNDATIONAL ANALYSIS PLANS, SELECTED KEY VENDORS, AND RECRUITED 635 PARTICIPANTS. ADDITIONALLY, 7 NEW CLINICAL SITES WERE ACTIVATED THROUGH LUCIN (SEE BELOW), AND A SUSTAINABLE FINANCIAL MODEL WITH A DEFINED MEMBERSHIP FEE STRUCTURE WAS ESTABLISHED. THE PROGRAM WAS PRESENTED AT 8 SCIENTIFIC CONFERENCES, HELPING TO SPREAD THE WORD ABOUT THE RESOURCE AVAILABLE TO THE RESEARCH COMMUNITY.LUPUS THERAPEUTICS,LLC:THE LRA FOUNDED LUPUS THERAPEUTICS, LLC (LT) AS THE CLINICAL RESEARCH AFFILIATE OF THE LRA IN 2018. WITH THIS ADDITION, THE LRA IS THE ONLY ORGANIZATION LEADING LUPUS RESEARCH ACROSS THE CONTINUUM FROM ACCELERATING BASIC DISCOVERIES IN THE LAB THROUGH CLINICAL EVALUATION OF NEW THERAPIES. LT IS ACTIVELY SUPPORTING SEVERAL CLINICAL STUDIES FOR NEW THERAPIES THROUGH THE LUPUS CLINICAL INVESTIGATORS NETWORK (LUCIN). LT OVERSEES LUCIN, A NORTH AMERICA-BASED LUPUS CLINICAL TRIALS NETWORK OF 60+ PREMIER RESEARCH MEDICAL CENTERS. THE LRA PROVIDED OVER $2.4 MILLION IN GRANTS IN 2025 TO CONTINUE FUNDING TOP ACADEMIC CENTERS TO FOSTER ROBUST, HIGH QUALITY CLINICAL TRIAL CONDUCT WITH PARTICIPATION ACROSS NORTH AMERICA.LT ALSO OFFERS EXPERTISE COMBINED WITH THAT OF 250+ LUCIN PROVIDERS AND THE LRA TO SUPPORT ACADEMIC, NONPROFIT AND BIOTECH AND PHARMACEUTICAL ORGANIZATIONS TO PLAN, INITIATE AND MANAGE CLINICAL RESEARCH. THIS OCCURS THROUGH DIVERSE ADVISORY SERVICES AND DIRECT CLINICAL OPERATIONS SUPPORT. AN ANNUAL LUCIN COMMUNITY MEETING IS HELD TO BRING TOGETHER ALL THE PARTNERS IN CLINICAL RESEARCH TO HIGHLIGHT RECENT ADVANCEMENTS, BOLSTER UNDERSTANDING, ADDRESS CURRENT CHALLENGES IN CLINICAL RESEARCH AND ENCOURAGE COLLABORATION FOR SUCCESSFUL DEVELOPMENT OF NEW TREATMENT APPROACHES.IN ADDITION, LT HAS EXPANDED THE FIRST PEER-TO-PEER CLINICAL TRIALS EDUCATION PROGRAM, PATIENT ADVOCATES FOR LUPUS STUDIES OR PALS TO INCLUDE TRIAL BUDDY SUPPORT DURING PARTICIPATION IN CLINICAL TRIALS. PALS AIMS TO IMPROVE CLINICAL RESEARCH AWARENESS, KNOWLEDGE AND ENROLLMENT, WITH A SPECIFIC FOCUS ON MAKING SURE POPULATIONS AT GREATEST RISK FOR LUPUS ARE WELL REPRESENTED IN STUDIES. LT ALSO SUPPORTS OTHER PATIENT ENGAGEMENT ACTIVITIES SUCH AS PATIENT ADVISORY BOARDS, PATIENT VISITS AND PATIENT PROTOCOL REVIEW COMMITTEES TO ENSURE THAT INDIVIDUALS IMPACTED BY LUPUS HAVE A VOICE IN THE TREATMENT DEVELOPMENT PROCESS. FINALLY, LT EFFORTS SUPPORT VARIOUS EDUCATION OFFERINGS FOR PROVIDERS AND PATIENTS, AND COMMUNITY-BASED OUTREACH TO ENSURE REPRESENTATIVE PARTICIPATION OF THE ENTIRE LUPUS COMMUNITY IN CLINICAL RESEARCH. 645427 40305 THE LUPUS RESEARCH ALLIANCE (LRA)'S ADVOCACY EFFORTS FOCUS ON EDUCATING CONGRESS ABOUT LUPUS AND URGING CONGRESS AND THE ADMINISTRATION TO PROVIDE THE FUNDS AND SUPPORT NEEDED TO ADVANCE LUPUS RESEARCH THAT CAN LEAD TO BETTER TREATMENTS AND, ULTIMATELY, A CURE. THE TOP GOALS OF THE LUPUS RESEARCH ALLIANCE PUBLIC POLICY PROGRAM FOCUS MAINLY ON FUNDING FOR LUPUS RESEARCH THAT WILL LEAD TO BETTER TREATMENTS FOR PEOPLE LIVING WITH LUPUS. GOALS INCLUDE: INCREASING FEDERAL FUNDING FOR LUPUS RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH (NIH), AND SPECIFICALLY THE NATIONAL INSTITUTE FOR ALLERGY & INFECTIOUS DISEASE (NIAID), AND THE NATIONAL INSTITUTE FOR ARTHRITIS & MUSCULOSKELETAL DISORDERS (NIAMS). ADDITIONALLY, THE LRA ADVOCATES FOR LUPUS RESEARCH THROUGH THE DEPARTMENT OF DEFENSE (DOD) CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS (CDMRP); SUPPORTING THE LUPUS ACCELERATING BREAKTHROUGHS CONSORTIUM (LUPUS ABC), THE LRA'S PARTNERSHIP WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA); AND ENSURING THE PATIENT VOICE IS INCORPORATED IN THE DRUG DEVELOPMENT PROCESS. VOLUNTEER ADVOCATES ACROSS THE COUNTRY HELP AMPLIFY THESE OUTREACH EFFORTS.THROUGH THE LRA'S ONGOING PUBLIC POLICY PROGRAM EFFORTS, CONGRESS HAS APPROPRIATED $75 MILLION FOR THE CDMRP LUPUS RESEARCH PROGRAM OPERATED BY THE ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND. GIVEN THE HIGH DEMAND FOR NEW RESEARCH ALONGSIDE THE RISING NUMBERS OF WOMEN TREATED AT MILITARY HEALTH FACILITIES, AS WELL AS THE LINK BETWEEN POST-TRAUMATIC STRESS DISORDER (PTSD) AND THE DEVELOPMENT OF AN AUTOIMMUNE DISEASE, THE LUPUS RESEARCH ALLIANCE HAS WORKED TO CONVINCE CONGRESS TO INCREASE ITS INVESTMENT AND PROVIDE $15 MILLION FOR THE LUPUS RESEARCH PROGRAM IN THE DEFENSE APPROPRIATIONS BILL. THIS ADDITIONAL INVESTMENT IS CRITICAL FOR DISCOVERIES THAT CAN MAKE A DIFFERENCE IN PATIENTS' ABILITY TO BE THE BEST VERSION OF THEMSELVES. THE LRA LED THE PUSH FOR THE CREATION OF THE LUPUS RESEARCH PROGRAM, WHICH WAS FIRST FUNDED WITH $5 MILLION IN 2017 AND INCREASED TO $10 MILLION PER YEAR IN 2020. IN 2025, THE FUNDING FOR THIS PROGRAM WAS NOT ALLOCATED IN THE BUDGET, LEADING THE LUPUS RESEARCH ALLIANCE TO PUSH FOR THIS FUNDING TO BE RESTORED IN THE FY26 BUDGET. LRA LEADERSHIP, ADVOCATES, AND ALLIED MEMBERS OF CONGRESS ARE WORKING TO ADVANCE RESEARCH PRIORITIES LIKE THIS THAT ARE CRITICAL TO THE LUPUS RESEARCH ALLIANCE AND ALL PEOPLE IMPACTED BY LUPUS. IN 2025, THE LRA CONTINUED WORK TO STAVE OFF PROPOSED CUTS TO MEDICAL RESEARCH AT THE NIH FOR LUPUS AND ALL DISEASES. LRA STAFF, LEADERSHIP, AND ADVOCATES ENGAGED IN MEETINGS WITH MEMBERS OF CONGRESS AND CONGRESSIONAL STAFF IN-PERSON, BY PHONE, AND THROUGH VIRTUAL MEETINGS, AND LRA ORGANIZED A CONGRESSIONAL BRIEFING IN COORDINATION WITH THE LEADERS OF THE BIPARTISAN CONGRESSIONAL LUPUS CAUCUS. TO SUPPORT THESE EFFORTS, THE LRA CREATED WRITTEN RESOURCES AND HELD VIRTUAL OFFICE HOUR SESSIONS TO ANSWER QUESTIONS, AND HELP ADVOCATES PREPARE TO SHARE THEIR STORIES AND EMPHASIZE THE IMPORTANCE OF RESEARCH FUNDING. ONGOING ADVOCACY FOCUSES ON ENACTING LEGISLATION THAT INCLUDES THE FEDERAL FUNDING NECESSARY TO SUPPORT INVESTIGATORS AND FOLLOW THROUGH WITH RESEARCH DISCOVERIES THAT WILL IMPROVE THE UNDERSTANDING OF AND TREATMENT FOR LUPUS. 33156485 1 1 0 1 0 0 0 0 0 1 1 0 0 0 1 0 0 1 0 0 1 1 0 1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 113 0 1 71 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 23 23 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN VA WA WV WI X X X DEBRA ROSE 6468846000 52 VANDERBILT AVE SUITE 401 NEW YORK NY 10017 IRA AKSELRAD CHAIR 1.00 X X 0 0 0 JOSEPH MAURIELLO TREASURER 1.00 X X 0 0 0 ANNA FISCH SECRETARY 1.00 X X 0 0 0 JAMES ANDREW DIRECTOR 1.00 X 0 0 0 BISHOP RUDY V CARLTON DIRECTOR 1.00 X 0 0 0 ANDREW C CHAN DIRECTOR 1.00 X 0 0 0 WILLIE COLON DIRECTOR 1.00 X 0 0 0 JENNIFER DAKIN DIRECTOR 1.00 X 0 0 0 JENNIE DESCHERER DIRECTOR 1.00 X 0 0 0 KATEY DRISCOLL DIRECTOR 1.00 X 0 0 0 JOE GERMANOTTA DIRECTOR 1.00 X 0 0 0 XAVIER GOSS DIRECTOR 1.00 X 0 0 0 DAVID KIES DIRECTOR 1.00 X 0 0 0 GARY KORETSKY DIRECTOR 1.00 X 0 0 0 VERONICA VARGAS LUPO DIRECTOR 1.00 X 0 0 0 NADEEM MEGHJI DIRECTOR 1.00 X 0 0 0 NIDHI PATEL DIRECTOR 1.00 X 0 0 0 LISA HERTZ ROBINSON DIRECTOR 1.00 X 0 0 0 ROBERT SEDER MD DIRECTOR 1.00 X 0 0 0 DANIEL J WALLACE DIRECTOR 1.00 X 0 0 0 JULIUS WILLIAMS DIRECTOR 1.00 X 0 0 0 WILLIAM WOLFE DIRECTOR 1.00 X 0 0 0 SPENCER ZWICK DIRECTOR 1.00 X 0 0 0 ALBERT T ROY CEO AND PRESIDENT 40.00 X 457769 0 96080 STACIE BELL PHD CHIEF CLINICAL RESEARCH OF 40.00 X 282244 0 50676 DEBRA ROSE CHIEF FINANCAL OFFICER 40.00 X 251485 0 88548 TEODORA STAEVA PHD CHIEF SCIENTIFIC OFFICER 40.00 X 339146 0 83817 ANDREA O'NEILL VP, DEVELOPMENT 40.00 X 270566 0 44585 NICOLE CAPOSSELA CHEIF ADVANCEMENT OFFICER 40.00 X 350753 0 41164 NISHANT RASTOGI MANAGING DIRECTOR, LUPUS VENTURES 40.00 X 63597 0 11016 PENELOPE MITCHELL VP OF COMMUNICATIONS 40.00 X 212381 0 47497 LUKE EASLEY VP OF HR & ADMINISTRATION 40.00 X 208977 0 42715 DEVON KELLY LUPUS NEXUS DIRECTOR 40.00 X 236282 0 45857 DOREY NEILINGER SENIOR DIRECTOR OF PHILANT 40.00 X 189027 0 47748 HOANG NGUYEN DIRECTOR OF SCIENTIFIC PAR 40.00 X 200171 0 39501 NIKOLAY NEPOCHATOV BIOINFORMATICS SOFTWARE ENGINEER 40.00 X 174534 0 50807 KENNETH M FARBER FORMER CEO & PRESIDENT 40.00 X 340000 0 0 JENNIFER MERIWETHER CLIN OPS DIRECTOR, LT 40.00 X 217433 0 39763 3794365 0 729774 38 1 1 0 EG&A CIRP DBA MCS HEALTHCARE PR 110 ALLEN ROAD SUITE 300 BASKING RIDGE NJ 07921 PUBLIC RELATIONS CONSULTANT 451156 CONVERGENCY LLCCONVERGENCY LLC 9117 FRIARS ROAD BETHESDA MD 20817 LUPUS ABC CONSULTANT 221473 SCHANER & LUBITZ PLLC 4550 MONTGOMERY AVE SUITE 1100 N BETHESDA MD 20814 LIFE SCIENCES ATTORNEY 154107 ULO CONSULTING PO BOX 1545 HAYES VA 23072 LUPUS NEXUS CONSULTANT 144625 LAUTMAN MASKA NEIL AND CO 1703 RHODE ISLAND AVE NW STE 301 WASHINGTON DC 20036 DIRECT RESPONSE CONSULTANT 126000 10 3829159 8217663 201792 12046822 LUCIN CONSULTING REVENUE 900099 2057382 2057382 2057382 1845334 1845334 25569105 18393098 7176007 7176007 7176007 882824 3829159 882824 0 SUBLET INCOME 900099 575904 575904 575904 23701449 2057382 0 9597245 15114743 15114743 40305 40305 896288 896288 3067690 1752855 581851 732984 7049998 4237075 1111532 1701391 569684 344041 85974 139669 1756547 1053488 275046 428013 718754 426696 118661 173397 203629 130274 31464 41891 62271 62271 197631 197631 78000 78000 110408 110408 2577068 1627414 440793 508861 150854 94891 29896 26067 2768465 2395772 242466 130227 902439 227036 582776 92627 630509 349450 160820 120239 1601340 1476787 98274 26279 131334 77984 21787 31563 75108 46045 11808 17255 CLINICAL STUDIES 2445430 2445430 PRINTING & PUBLICATIONS 428477 68476 65294 294707 POSTAGE, SHIPPING & DEL 240155 37758 20248 182149 DATA PROCESSING 120840 31785 11624 77431 211963 84261 46167 81535 42149930 33156485 4109160 4884285 3033725 1904566 259307 103720 13309587 3699420 281210 601662 635827 836617 1324535 1023518 182047 301017 73055389 76897060 598131 637726 1899193 3336368 93254416 88318156 2313310 1981020 32647877 34129830 2580654 3529179 37541841 39640029 X 34833646 38380621 20878929 10297506 55712575 48678127 93254416 88318156 X -18448481 10831430 582603 X 0 1 X 1 0 X 18941837 18375553 41038661 11172604 12046822 101575477 18941837 18375553 41038661 11172604 12046822 101575477 39388051 62187426 2025770 2655902 1929526 1867297 1845334 10323829 111899306 7399113 0.55570 0.44800 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 645427 645427 41504503 42149930 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 622162 761506 571134 645427 2600229 250000 250000 250000 250000 1000000 1500000 50605471 12218791 5354071 57470191 51925078 2690242 4009849 50605471 53986019 1956112 4017053 51925078 61314537 -3669040 3659722 53986019 56586437 7839333 3111233 61314537 1.00000 0 0 548216 384047 164169 776319 639471 136848 301017 OPERATING LEASE LIABILITIES 3529179 3529179 35005074 10831430 582603 11414033 23591041 110408 110408 23701449 42039522 0 42039522 110408 110408 42149930 PART V, LINE 4: BOARD DESIGNATED (QUASI) ENDOWMENT FUND INCOME TO BE USED FOR SUPPORTING OPERATIONS AND THE RESEARCH PROGRAM. PRINCIPAL TO REMAIN INTACT UNLESS HIGH PRIORITY LUPUS RESEARCH PROJECTS NEED TO BE FUNDED THAT COULD NOT BE FUNDED OTHERWISE. 1 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 GRANTS TO RECIPIENTS 417676 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS TO RECIPIENTS 478612 0 0 0 0 0 0 896288 0 896288 NORTH AMERICA LUPUS RESEARCH 77522 ACH 0 NORTH AMERICA LUPUS RESEARCH 15000 ACH 0 NORTH AMERICA LUPUS RESEARCH 44892 WIRE 0 NORTH AMERICA LUPUS RESEARCH 30785 CHECK 0 NORTH AMERICA LUPUS RESEARCH 51886 CHECK 0 NORTH AMERICA LUPUS RESEARCH 23000 CHECK 0 NORTH AMERICA LUPUS RESEARCH 15000 CHECK 0 NORTH AMERICA LUPUS RESEARCH 32461 ACH 0 NORTH AMERICA LUPUS RESEARCH 30391 CHECK 0 NORTH AMERICA LUPUS RESEARCH 8000 ACH 0 NORTH AMERICA LUPUS RESEARCH 88739 CHECK 0 EUROPE (INCLUDING ICELAND AND GREENLAND) LUPUS RESEARCH 17420 WIRE 0 EUROPE (INCLUDING ICELAND AND GREENLAND) LUPUS RESEARCH 8719 WIRE 0 EUROPE (INCLUDING ICELAND AND GREENLAND) LUPUS RESEARCH 490510 WIRE 0 11 3 0 0 0 0 0 0 PART I, LINE 2: PRE AWARD AND APPLICATION PHASE: BEFORE A GRANT IS AWARDED, DURING THE APPLICATION PHASE, THE SPONSORING INSTITUTION (SI) MUST AGREE THAT THEY WILL AGREE TO THE TERMS AND CONDITIONS OUTLINED IN THE LUPUS RESEARCH ALLIANCE (LRA)'S GRANT-SPECIFIC POLICY STATEMENT FOR RESEARCH GRANTS THAT INCLUDE: A. CONFIRMATION BY THE PRINCIPAL INVESTIGATOR (PI) AND THE SI THAT FUNDS WILL ONLY BE USED AS DESCRIBED IN THE APPLICATION SUBMITTED AND APPROVED FOR FUNDING. B. AGREE THAT PI AND SI ARE BOTH RESPONSIBLE FOR INSURING THAT ALL RESEARCH ACTIVITIES ARE CONDUCTED IN A SAFE, RESPONSIBLE AND ETHICAL MANNER. THEY MUST KEEP UPDATED APPROVAL FROM THE SI'S INSTITUTIONAL REVIEW BOARD AND ANIMAL CARE AND USE COMMITTEE THROUGHOUT THE PROJECT PERIOD. C. AGREE TO GET APPROVAL FROM THE LRA IF THERE NEEDS TO BE A SIGNIFICANT CHANGE TO THE BUDGET AS SUBMITTED. D. AGREE TO GET APPROVAL FROM THE LRA IF ADDITIONAL TIME IS NEEDED TO COMPLETE THE PROJECT WORK. E. AGREE TO SUBMIT ALL DELIVERABLES AND REPORTS AS SCHEDULED: (A) ANNUAL PROGRESS REPORTS AND (B) ANNUAL FINANCIAL REPORTS ARE REQUIRED. F. TRAVEL FUNDS PROVIDED AS PART OF THE PROJECT ARE EXPECTED TO BE USED TO ATTEND THE LRA'S ANNUAL MEETING - FORUM FOR DISCOVERY. G. CONFIRMATION THAT THERE IS NO OTHER ACTIVE OR PENDING SUPPORT FOR THE SPECIFIC PROJECT THAT IS THE SUBJECT OF THE GRANT. POST AWARD PROJECT PHASE: THE PI AND A REPRESENTATIVE FROM THE SI MUST SUBMIT A SIGNED LETTER OF ACCEPTANCE CONFIRMING THE FOLLOWING: A. PI'S WILLINGNESS TO ADHERE TO THE TERMS OF THE BUDGET AS OUTLINED IN THE FUNDING LETTER. B. PI'S WILLINGNESS TO COMPLY WITH ALL OF THE CONDITIONS OUTLINED IN THE POLICY STATEMENT FOR RESEARCH GRANTS AND PATENT AND INTELLECTUAL PROPERTY POLICY. C. THAT THERE IS NO OVERLAPPING SOURCE OF SUPPORT FOR THE PROJECT THAT IS THE SUBJECT OF THE AWARD. OTHER FUNDING THAT MIGHT BE CONSTRUED AS OVERLAPPING, MUST BE EXPLAINED IN DETAIL. D. THAT THE PI WILL ACCEPT RESPONSIBILITY FOR THE SCIENTIFIC AND TECHNICAL CONDUCT OF THE PROJECT AND FOR THE PROVISION OF ALL PROGRESS REPORTS REQUIRED FROM INVESTIGATORS FUNDED BY A GRANT FROM THE LRA. E. PI'S WILLINGNESS TO COMPLETE A BRIEF SURVEY AND SUBMIT A COPY OF THEIR UP-TO-DATE CV TO THE LRA TWO AND FIVE YEARS AFTER THE GRANT END DATE. ALL SI'S RECEIVE A PAYMENT AND DELIVERABLES SCHEDULE AND THE PROJECT IS MONITORED BY: A. PERIODIC PROGRESS REPORTS B. PERIODIC FINAL REPORTS C. ANNUAL MILESTONES SCHEDULE D. ADHERENCE TO LRA TERMS AND CONDITIONS GRANT CHANGES: WHEN EXTENSIONS ARE AWARDED, ADDITIONAL PROGRESS REPORTS AND FINANCIAL REPORTS ARE REQUIRED. AT THE END OF THE GRANT, FINAL PROGRESS AND FINANCIAL REPORTS ARE REQUIRED; UNSPENT AMOUNTS OVER $500 ARE TO BE RETURNED TO THE LRA. A. THE LRA MUST BE LISTED AS A FUNDER IN ANY PUBLISHED PAPERS AND ORAL OR POSTER PRESENTATIONS. B. THE SI MUST SUBMIT A COPY OF THE IRS DETERMINATION LETTER OR OTHER TAX GOVERNING INSTITUTION CONFIRMING THE TAX STATUS OF THE SI. X X X X X 1 DS CONSULTING GROUP 757 THIRD AVE 20TH FL NEW YORK NY 10017 SPECIAL EVENT CONSULTANT NY GALA 1 2756174 78000 2756174 2756174 78000 2756174 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX VT VA WA WV WI WY GALA CELEBRATION 3928958 3147808 781150 176609 232429 372112 WALK-A-THONS 783025 681351 101674 3230 80765 6124 11555 4711983 3829159 882824 3230 80765 182733 232429 383667 882824 0 SCHEDULE G, PART I, LINE 2B, COLUMN (V) DS CONSULTING PLANNED AND MANAGED LRA'S GALA EVENT. CONTRACT AMOUNT FOR THE PERIOD COVERING 1/1/25 - 12/31/25 WAS $78,000 PLUS REIMBURSABLE EXPENSES. 1 ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 472209056 501(C)(3) 22386 0 LUPUS RESEARCH BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 16088 0 LUPUS RESEARCH BRIGHAM AND WOMEN'S HOSPITAL 77 AVENUE LOUIS PASTEUR BOSTON MA 02115 042312909 501(C)(3) 3037963 0 LUPUS RESEARCH BOSTON CHILDREN'S HOSPTIAL 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 167680 0 LUPUS RESEARCH CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES CA 90048 951644600 501(C)(3) 2815610 0 LUPUS RESEARCH COLUMBIA UNIVERSITY MEDICAL CENTER 154 HAVEN AVE 2ND FL NEW YORK NY 10032 133598093 501(C)(3) 49416 0 LUPUS RESEARCH EMORY UNIVERSITY 1762 CLIFTON RD NE ATLANTA GA 30322 580566256 501(C)(3) 552746 0 LUPUS RESEARCH FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH 350 COMMUNITY DRIVE MANHASSET NY 11030 112673595 501(C)(3) 32890 0 LUPUS RESEARCH FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH 9650 ROCKVILLE PIKE BETHESDA MD 20814 521986675 501(C)(3) 100000 0 LUPUS RESEARCH GEORGETOWN UNIVERSITY MEDICAL CENTER 3970 RERSERVOIR RD NW WASHINGTON DC 20057 530196603 501(C)(3) 26000 0 LUPUS RESEARCH HOSPITAL FOR SPECIAL SURGERY 535 E 70TH STREET NEW YORK NY 10021 131624135 501(C)(3) 84731 0 LUPUS RESEARCH MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 30328 0 LUPUS RESEARCH MAYO CLINIC 200 FIRST STREET SW ROCHESTER MN 55905 416011702 501(C)(3) 41303 0 LUPUS RESEARCH MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 32224 593337028 501(C)(3) 47150 0 LUPUS RESEARCH MEDICAL UNIVERSITY OF SOUTH CAROLINA 179 ASHLEY AVENUE CHARLESTON SC 29425 576028985 115966 0 LUPUS RESEARCH MEMORIAL SLOAN-KETTERING CANCER CENTER 633 THIRD AVE 4TH FL NEW YORK NY 10017 131924236 501(C)(3) 302573 0 LUPUS RESEARCH NYU LANGONE HOSPITALS JOSEPH S AND DIANE H STEINBERG AMBULATORY CARE CEN 70 ATLANTIC AVE BROOKLYN NY 11201 133971298 501(C)(3) 15000 0 LUPUS RESEARCH NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVENUE NEW YORK NY 10016 135562308 501(C)(3) 118887 0 LUPUS RESEARCH NORTHWELL HEALTH - DIVISION OF RHEUMATOLOGY 972 BRUSH HOLLOW RD 5TH FL WESTBURY NY 11590 112673595 501(C)(3) 50627 0 LUPUS RESEARCH NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 362167818 501(C)(3) 47942 0 LUPUS RESEARCH OKLAHOMA MEDICAL RESEARCH FOUNDATION 825 NE 13TH STREET OKLAHOMA CITY OK 73104 730580274 501(C)(3) 77661 0 LUPUS RESEARCH PENNSYLVANIA STATE UNIVERSITY ONE OLD MAIN UNIVERSITY PARK PA 16802 246000376 501(C)(3) 610890 0 LUPUS RESEARCH REGENTS OF THE UNIVERSITY OF CALIFORNIA IRVINE 5171 CALIFORNIA AVENUE STE 150 IRVINE CA 92697 952226406 501(C)(3) 38595 0 LUPUS RESEARCH REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC0934 LA JOLLA CA 92093 956006144 501(C)(3) 812485 0 LUPUS RESEARCH RUSH UNIVERSITY MEDICAL CENTER 1653 WEST CONGRESS PARKWAY CHICAGO IL 60612 362174823 501(C)(3) 29875 0 LUPUS RESEARCH STANFORD UNIVERSITY 3145 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 320175 0 LUPUS RESEARCH STATE UNIVERSITY OF NY AT STONY BROOK ONE LINCOLN CENTER SYRACUSE NY 13202 141368361 501(C)(3) 32000 0 LUPUS RESEARCH THE METROHEALTH SYSTEM 2500 METROHEALTH DRIVE CLEVELAND OH 44109 346004382 25125 0 LUPUS RESEARCH THE OHIO STATE UNIVERSITY 1960 KENNY ROAD COLUMBUS OH 43210 311702164 31160 0 LUPUS RESEARCH REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES 10920 WILSHIRE BLVD STE 620 LOS ANGELES CA 90024 956006143 501(C)(3) 76108 0 LUPUS RESEARCH THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE STE 501 CHICAGO IL 60637 362177139 501(C)(3) 32200 0 LUPUS RESEARCH THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 6000 FELDWOOD ROAD COLLEGE PARK GA 30349 566001393 501(C)(3) 147511 0 LUPUS RESEARCH TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA PA 19104 231352685 501(C)(3) 1344967 0 LUPUS RESEARCH UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 3RD AVE S BIRMINGHAM AL 35294 636005396 501(C)(3) 58100 0 LUPUS RESEARCH UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE TUCSON 1501 N CAMPBELL AVE TUCSON AZ 85724 742652689 40656 0 LUPUS RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO 2200 UNIVERSITY HALL BERKELEY CA 94720 946036493 501(C)(3) 72940 0 LUPUS RESEARCH UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS 3100 MARINE ST 6TH FL BOULDER CO 80309 846000555 501(C)(3) 442073 0 LUPUS RESEARCH UNIVERSITY OF FLORIDA 207 TIGERT HALL GAINSEVILLE FL 32611 596002052 29859 0 LUPUS RESEARCH UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE 3901 RAINBOW BLVD KANSAS CITY KS 66160 481108830 501(C)(3) 22779 0 LUPUS RESEARCH UNIVERSITY OF MARYLAND BALTIMORE 620 W LEXINGON STREET 4TH FL BALTIMORE MD 21201 521830242 58860 0 LUPUS RESEARCH UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUENORTH WORCESTER MA 01655 043167352 146058 0 LUPUS RESEARCH UNIVERSITY OF MIAMI 1320 S DIXIE HIGHWAY GABLES ONE TOWER 650 CORAL GABLES FL 33146 590624458 501(C)(3) 62188 0 LUPUS RESEARCH UNIVERSITY OF MICHIGAN 503 THOMPSON STREET ANN ARBOR MI 48109 386006309 501(C)(3) 333441 0 LUPUS RESEARCH ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L LEVY PL NEW YORK NY 10029 136171197 501(C)(3) 449585 0 LUPUS RESEARCH UNIVERSITY OF NEBRASKA MEDICAL CENTER 988145 NEBRASKA MEDICA CTR OMAHA NE 68198 911858433 501(C)(3) 30770 0 LUPUS RESEARCH UNIVERSITY OF NEVADA LAS VEGAS 4505 S MARYLAND PARKWAY LAS VEGAS NV 89154 886000024 40536 0 LUPUS RESEARCH UNIVERSITY OF PITTSBURGH 123 UNIVERSITY PLACE PITTSBURGH PA 15213 250965591 501(C)(3) 93029 0 LUPUS RESEARCH UNIVERSITY OF ROCHESTER 518 HYLAN BUILDING ROCHESTER NY 14627 160743209 501(C)(3) 35498 0 LUPUS RESEARCH UNIVERSITY OF SOUTHERN CALIFORNIA 1640 MARENGO STREET 7TH FL LOS ANGELES CA 90033 951642394 501(C)(3) 25795 0 LUPUS RESEARCH UNIVERSITY OF WASHINGTON 3917 UNIVERSITY WAY NE SEATTLE WA 98195 916001537 327414 0 LUPUS RESEARCH UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 746000203 62887 0 LUPUS RESEARCH VANDERBILT UNIVERSITY MEDICAL CENTER 1211 MEDICAL CENTER DRIVE NASHVILLE TN 37232 352528741 501(C)(3) 63370 0 LUPUS RESEARCH WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BLVD WINSTONSALEM NC 27157 223849199 501(C)(3) 24743 0 LUPUS RESEARCH WALLACE RHEUMATIC STUDIES CENTER LLC 8737 BENVERLY BLVD STE 301 W HOLLYWOOD CA 90048 455434561 501(C)(3) 68184 0 LUPUS RESEARCH WASHINGTON UNIVERSITY SCHOOL OF MEDICINE MISSOURI ONE BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501(C)(3) 27185 0 LUPUS RESEARCH WEILL CORNELL MEDICAL COLLEGE 1300 YORK AVENUE NEW YORK NY 10065 131623978 501(C)(3) 10000 0 LUPUS RESEARCH YALE UNIVERSITY BOX 208239 NEW HAVEN CT 06520 060646973 501(C)(3) 121813 0 LUPUS RESEARCH UNIVERSITY OF VIRGINIA 1001 N EMMET ST CHARLOTTESVILLE VA 22903 546001796 501(C)(3) 577127 0 LUPUS RESEARCH BREAKTHROUGH T1D 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 231907729 501(C)(3) 224989 0 LUPUS RESEARCH OREGON HEALTH AND SCIENCE UNIVERSITY 3181 SAM JACKSON PARK ROAD PORTLAND OR 97239 931176109 501(C)(3) 26000 0 LUPUS RESEARCH PROVIDENCE ST JOSEPH HEALTH 1801 LIND AVE SW RENTON WA 98057 811244422 501(C)(3) 33482 0 LUPUS RESEARCH FASEB 6120 EXECUTIVE BLVD STE 230 ROCKVILLE MD 20852 520700497 501(C)(3) 6000 0 LUPUS RESEARCH JOHNS HOPKINS UNIVERSITY 3400 N CHARLES ST BALTIMORE MD 21218 520595110 501(C)(3) 288825 0 LUPUS RESEARCH UNIVERSITY OF HOUSTON 4800 CALHOUN ROAD HOUSTON TX 77004 746001399 501(C)(3) 33248 0 LUPUS RESEARCH SEATTLE CHILDRENS HOSPITAL 818 STEWART ST SEATTLE WA 98145 910564748 501(C)(3) 29083 0 LUPUS RESEARCH LUPUS EMERGENCY GRANT- $500 MAX PER PERSON 84 40305 BILLS LUPUS EMERGENCY GRANT- $500 MAX PER PERSON PART I, LINE 2: PRE AWARD AND APPLICATION PHASE: BEFORE A GRANT IS AWARDED, DURING THE APPLICATION PHASE, THE SPONSORING INSTITUTION (SI) MUST AGREE THAT THEY WILL AGREE TO THE TERMS AND CONDITIONS OUTLINED IN THE LUPUS RESEARCH ALLIANCE (LRA)'S GRANT-SPECIFIC POLICY STATEMENT FOR RESEARCH GRANTS THAT INCLUDE: A. CONFIRMATION BY THE PRINCIPAL INVESTIGATOR (PI) AND THE SI THAT FUNDS WILL ONLY BE USED AS DESCRIBED IN THE APPLICATION SUBMITTED AND APPROVED FOR FUNDING. B. AGREE THAT THE PI AND SI ARE BOTH RESPONSIBLE FOR INSURING THAT ALL RESEARCH ACTIVITIES ARE CONDUCTED IN A SAFE, RESPONSIBLE AND ETHICAL MANNER. THEY MUST KEEP UPDATED APPROVAL FROM THE SI'S INSTITUTIONAL REVIEW BOARD AND ANIMAL CARE AND USE COMMITTEE THROUGHOUT THE PROJECT PERIOD. C. AGREE TO GET APPROVAL FROM THE LRA IF THERE NEEDS TO BE A SIGNIFICANT CHANGE TO THE BUDGET AS SUBMITTED. D. AGREE TO GET APPROVAL FROM THE LRA IF ADDITIONAL TIME IS NEEDED TO COMPLETE THE PROJECT WORK. E. AGREE TO SUBMIT ALL DELIVERABLES AND REPORTS AS SCHEDULED: (A) ANNUAL PROGRESS REPORTS AND (B) ANNUAL FINANCIAL REPORTS ARE REQUIRED. F. TRAVEL FUNDS PROVIDED AS PART OF THE PROJECT ARE EXPECTED TO BE USED TO ATTEND THE LRA'S ANNUAL MEETING - FORUM FOR DISCOVERY. G. CONFIRMATION THAT THERE IS NO OTHER ACTIVE OR PENDING SUPPORT FOR THE SPECIFIC PROJECT THAT IS THE SUBJECT OF THE GRANT. POST AWARD PROJECT PHASE: THE PI AND A REPRESENTATIVE FROM THE SI MUST SUBMIT A SIGNED LETTER OF ACCEPTANCE CONFIRMING THE FOLLOWING: A. PI'S WILLINGNESS TO ADHERE TO THE TERMS OF THE BUDGET AS OUTLINED IN THE FUNDING LETTER. B. PI'S WILLINGNESS TO COMPLY WITH ALL OF THE CONDITIONS OUTLINED IN THE POLICY STATEMENT FOR RESEARCH GRANTS AND PATENT AND INTELLECTUAL PROPERTY POLICY. C. THAT THERE IS NO OVERLAPPING SOURCE OF SUPPORT FOR THE PROJEC TTHAT IS THE SUBJECT OF THE AWARD. OTHER FUNDING THAT MIGHT BE CONSTRUED AS OVERLAPPING, MUST BE EXPLAINED IN DETAIL. D. THAT THE PI WILL ACCEPT RESPONSIBILITY FOR THE SCIENTIFIC AND TECHNICAL CONDUCT OF THE PROJECT AND FOR THE PROVISION OF ALL PROGRESS REPORTS REQUIRED FROM INVESTIGATORS FUNDED BY A GRANT FROM THE LRA. E. PI'S WILLINGNESS TO COMPLETE A BRIEF SURVEY AND SUBMIT A COPY OF THEIR UP-TO-DATE CV TO THE LRA TWO AND FIVE YEARS AFTER THE GRANT END DATE. ALL SI'S RECEIVE A PAYMENT AND DELIVERABLES SCHEDULE AND THE PROJECT IS MONITORED BY: A. PERIODIC PROGRESS REPORTS B. PERIODIC FINAL REPORTS C. ANNUAL MILESTONE SCHEDULE D. ADHERENCE TO LRA TERMS AND CONDITIONS GRANT CHANGES: WHEN EXTENSIONS ARE AWARDED, ADDITIONAL PROGRESS REPORTS AND FINANCIAL REPORTS ARE REQUIRED. AT THE END OF THE GRANT, FINAL PROGRESS AND FINANCIAL REPORTS ARE REQUIRED; UNSPENT AMOUNTS OVER $500 ARE TO BE RETURNED TO THE LRA. THE LRA MUST BE LISTED AS A FUNDER IN ANY PUBLISHED PAPERS AND ORAL OR POSTER PRESENTATIONS. THE SI MUST SUBMIT A COPY OF THE IRS DETERMINATION LETTER OR OTHER TAX GOVERNING INSTITUTION CONFIRMING THE TAX STATUS OF THE SI. X X X X X X 0 0 0 0 0 0 0 0 0 ALBERT T ROY CEO AND PRESIDENT 369801 0 85000 0 2968 0 34500 0 61580 0 553849 0 0 0 STACIE BELL PHD CHIEF CLINICAL RESEARCH OF 268900 0 10000 0 3344 0 24000 0 26676 0 332920 0 0 0 DEBRA ROSE CHIEF FINANCAL OFFICER 238620 0 10000 0 2865 0 31301 0 57247 0 340033 0 0 0 TEODORA STAEVA PHD CHIEF SCIENTIFIC OFFICER 286934 0 50000 0 2212 0 34481 0 49336 0 422963 0 0 0 ANDREA O'NEILL VP, DEVELOPMENT 252482 0 15000 0 3084 0 26964 0 17621 0 315151 0 0 0 NICOLE CAPOSSELA CHEIF ADVANCEMENT OFFICER 299175 0 50000 0 1578 0 0 0 41164 0 391917 0 0 0 PENELOPE MITCHELL VP OF COMMUNICATIONS 193872 0 15000 0 3509 0 20720 0 26777 0 259878 0 0 0 LUKE EASLEY VP OF HR & ADMINISTRATION 207813 0 0 0 1164 0 18553 0 24162 0 251692 0 0 0 DEVON KELLY LUPUS NEXUS DIRECTOR 223554 0 9042 0 3686 0 18084 0 27773 0 282139 0 0 0 DOREY NEILINGER SENIOR DIRECTOR OF PHILANT 185306 0 0 0 3721 0 20530 0 27218 0 236775 0 0 0 HOANG NGUYEN DIRECTOR OF SCIENTIFIC PAR 188100 0 10000 0 2071 0 13439 0 26062 0 239672 0 0 0 NIKOLAY NEPOCHATOV BIOINFORMATICS SOFTWARE ENGINEER 173652 0 0 0 882 0 17233 0 33574 0 225341 0 0 0 KENNETH M FARBER FORMER CEO & PRESIDENT 340000 0 0 0 0 0 0 0 0 0 340000 0 0 0 JENNIFER MERIWETHER CLIN OPS DIRECTOR, LT 205752 0 10288 0 1393 0 15827 0 23936 0 257196 0 0 0 X 8 201792 AVG STOCK VALUE 0 1 1 PART I, LINE 32B: LRA HAS AN ACCOUNT WITH MORGAN STANLEY, WHICH LRA USES TO SELL THE CONTRIBUTIONS IT RECEIVES THOUGH STOCKS. FORM 990, PART VI, SECTION A, LINE 1A EXECUTIVE COMMITTEE IS COMPRISED OF THE BOARD CO-CHAIRS, PRESIDENT, BOARD SECRETARY AND ONE ADDITIONAL VOTING BOARD MEMBER. THE EXECUTIVE COMMITTEE APPROVES DETAILS OF PROGRAMS ALREADY APPROVED BY THE BOARD, STAFF COMPENSATION AND LARGE CONTRACT NEGOTIATIONS. FORM 990, PART VI, SECTION A, LINE 2 IRA AKSELRAD AND ROBERT WOOD JOHNSON, IV (PAST CHAIRMAN OF THE BOARD), HAVE A BUSINESS RELATIONSHIP. RICHARD K. DESCHERER (CO-CHAIR) AND JENNIE DESCHERER HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B AFTER PREPARATION OF FORM 990 BY LRA'S AUDITOR, LUTZ AND CARR, THE 990 IS REVIEWED BY THE LRA'S EXECUTIVE OFFICERS, THE CHIEF FINANCIAL OFFICER AND THE PRESIDENT. THE FINANCE AND AUDIT COMMITTEE OF THE BOARD THEN MEETS TO REVIEW THE 990 BEFORE FILING AND APPROVES FOR FILING WITH ANY NOTED CHANGES. A DRAFT OF THE 990 IS THEN SENT OUT TO THE FULL BOARD FOR COMMENT PRIOR TO FILING WITH THE IRS. THE FINAL FORM 990 IS PRESENTED TO THE FULL BOARD AT THE NEXT SCHEDULED MEETING. FORM 990, PART VI, SECTION B, LINE 12C THE EXECUTIVE COMMITTEE OF THE BOARD IS RESPONSIBLE FOR MONITORING CONFLICTS OF INTEREST. AN ANNUAL CONFLICT OF INTEREST DISCLOSURE FORM IS REQUIRED TO BE FILLED OUT EACH YEAR BY BOARD MEMBERS, OFFICERS AND KEY EMPLOYEES. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ASSISTED THE BOARD IN FULFILLING ITS OVERSIGHT RESPONSIBILITIES RELATING TO THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND OTHER EXECUTIVE OFFICERS; AND PROVIDED RECOMMENDATIONS REGARDING MANAGEMENT SUCCESSORS. ANNUALLY THE COMMITTEE REVIEWS AND RECOMMENDS TO THE BOARD THE SALARY FOR THE PRESIDENT AND OTHER OFFICERS/KEY EMPLOYEES. IN 2025, THE COMMITTEE REVIEWED AND APPROVED BASE SALARIES, 2026 COMPENSATION PLAN INCLUDING THE 2025 YEAR-END BONUS POOL FOR ALL STAFF AND THE 403B NON-ELECTIVE EMPLOYER CONTRIBUTION TO ALL ELIGIBLE STAFF. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST, THE CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE ALSO AVAILABLE UPON REQUEST AND ARE ON THE FINANCIALS PAGE OF OUR WEBSITE AND ON GUIDESTAR.ORG FORM 990, PART XI, LINE 9: CANCELLED GRANTS 582,603. FORM 990, PART V, QUESTION 2A THE LRA CONTRACTS WITH TRINET, A PROFESSIONAL EMPLOYER ORGANIZATION (PEO), TO PROVIDE PAYROLL AND BENEFITS AS A CO-EMPLOYER WITH THE LRA. LRA PAYROLL AND BENEFITS ARE ADMINISTERED BY TRINET AS APPROVED BY LRA OFFICERS. LRA PAYROLL IS THEREFORE UNDER THE TRINET EIN: 13-3867443 AND W-2'S ARE PREPARED UNDER THAT EIN BY TRINET. LUPUS THERAPEUTICS LLC 52 VANDERBILT AVE SUITE 401 NEW YORK NY 10017 823984908 LRA'S CLINICAL TRIAL AFFILIATE, OVERSEEING CLINICAL RESEARCH ACTIVITY NY 3236521 501280 YES LUPUS VENTURES LLC 52 VANDERBILT AVE SUITE 401 NEW YORK NY 10017 582492929 LRA'S VENTURE INVESTMENT FUND NY 0 361524 YES